letter dated September 5, 2022 wherein the Company had informed that the

31st Annual General Meeting (AGM) of the Company is scheduled to be held on Thursday,

September 29, 2022 through Video Conferencing / Other Audio-Visual Means, in accordance with

the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board

of India (SEBI).

In terms of the requirements of Regulation 34(1) of the SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company,

for the financial year 2021-22, which has been sent through electronic mode to the Members.

The Annual Report, containing the Notice of AGM is enclosed and the same is uploaded on the

Company’s website at https://www.caplinpoint.net/index.php/annual-report/

This is for your kind information and records.

Kindly acknowledge the receipt.

Thanking You,

Sincerely yours,

For Caplin Point Laboratories Limited

Venkatram G

General Counsel & Company Secretary

Encl: A/a

VENKATRAM

GANAPATHISUBRAM

ANIAN

Digitally signed by VENKATRAM

GANAPATHISUBRAMANIAN

Date: 2022.09.08 07:48:44 +05'30':

Managing Director of Caplin Point Laboratories, he spearheads their rapid growth with a global footprint.

Previously, he has held leadership positions in several international assignments and has expertise not only in

the industry but also in unique needs of developing countries in South Asia, Middle East and Africa.

05'6$7+<$1$5$<$1$1

Mr D Sathyanarayanan has over 30 years of experience in the application development and implementation of

VRIWZDUHDQGKHEULQJVYDOXDEOHH[SHUWLVHWRH[SDQGWRQHZKRUL]RQV+HZDVWKH&KLHI7HFKQRORJ\2IÀFHURI

MedTech India a health care solutions provider.

He has a Bachelor’s degree from Indian Institute of Technology and a Master of Science from Stanford University.

%ULHISURÀOHVRIWKH%RDUGRI'LUHFWRUV

0597+,580$/$,

Mr. V Thirumalai is a post graduate in commerce . Mr. V Thirumalai has more than 5 decades of rich experience,

expertise and knowledge in the areas Finance, HR, Business administration, Management and Industrial

Relations.

24 | Annual Report 2021-22:

Managing Director

On Caplin’s strategic pursuit

Caplin works with 14,000 pharmacies to reach the BOP of the

markets.

(1'72(1'%86,1(6602'(/ 

With addition of Key Starting Material manufacturing capabilities

at the backend; pharmacy automation through health portal at the

forward end; and functioning of Clinical Research facility, we are

truly progressing towards being present across the industry value

chain. Caplin already has strong capabilities across APIs, Finished

Dosage, Manufacturing, R&D, Marketing & Distribution.

,1&5($6,1*)25:$5' %$&.:$5',17(*5$7,21

Caplin is targeting complete backward integration from Key

Starting Material (KSM) to Intermediates and API.Company targets

EHLQJEDFNZDUGLQWHJUDWHGZLWKRZQ$3,VIRURIDOO86ÀOLQJV

by 2024.

,1&5($6,1* 7+( 6+$5( 2) ,1129$7,9(  %5$1'('

352'8&76

Caplin Steriles Limited (CSL), our Subsidiary, has completed the

LQVWDOODWLRQ RI 3UH0L[HG %DJV OLQH &RPSDQ\ WR VWDUW ÀOLQJ 3UH

Mixed Bag products in the US by Q4FY2023

)< KDV EHHQ D GHÀQLQJ PLOHVWRQH LQ &DSOLQ·V MRXUQH\ RI

excellence. The year under review marked highest ever total

revenues, lucrative cash reserves, venturing in new products,

embracing newer technology & infrastructure facilities and

progress towards entry into newer markets.

During FY22, Caplin continued its strategic agenda anchored

DURXQGIROORZLQJNH\SLOODUV

Î Serving Bottom of Pyramid of the market

Î End-to-End Business model

Î Increasing forward & backward integration

Î Increasing the share of innovative & branded products

Î Firm progress on growth & expansion

Î Cost Leadership

Î Prudent Financial Management

6(59,1*%277202)3<5$0,'2)7+(0$5.(7 

From the time when Caplin started its journey from the less

travelled path i.e. choosing to serve Bottom of Pyramid Latin

American markets, it has come a long way to be India’s leading

pharma player in this region.

Today 90% of our revenues come from LATAM (87%) and Africa

(3%).

'565,'+$5*$1(6$1

26 | Annual Report 2021-22:

Managing Director, CFO and Independent Director and other

important executives of the Company. In addition, the Company’s

senior leadership team undertakes various risk governance

measures at the operational level as per the requirements. While

every company, as part of its risk management strategy, tries to put

in place mitigation measures to the extent possible, risks cannot

be wished away. We have listed a summarised account of some of

our key risks and mitigation measures drawn from management

reviews and deliberations of IRMC.

6RPHRIWKHLGHQWLÀHGULVNVDQGLWVPLWLJDWLRQVWUDWHJ\

*(2*5$3+,&$/5,6.

'HSHQGHQFHRIWKH&RPSDQ\RQDVSHFLÀFJHRJUDSK\FDQDIIHFW

balanced growth.

0,7,*$7,21675$7(*<

The Company has a strong presence in Latin America. On one

hand, the Company is enlarging its presence in Latin America and

on the other hand the Company has been gradually stepping up its

presence into US and other regulated markets, which will reduce

its dependency in Latin America in future.

MANAGEMENT REPORTS

Annual Report 2021-22 | 47

STANDALONE FINANCIAL STATEMENTS

CORPORATE OVERVIEW

CONSOLIDATED FINANCIAL STATEMENTS

NOTICE:

Managing Director, five Independent Directors and a

Non-Executive - Non- Independent Director.

Dr. R Ravichandran (DIN: 01920603), Independent Director

retired on May 11, 2021 (close of business hours), upon

completion of his tenure. Further, Mr. D P Mishra (DIN:

02032818), Non - Executive Non - Independent Director

tendered his resignation with effect from the closing hours

of July 11, 2022. The Board wishes to place on record their

valuable guidance and directions provided during their tenure

as Directors of the Company.

The term of appointment of Dr K C John (DIN: 01067374)

as Independent Director ended on August 24, 2022. The

term of appointment of Mr V Thirumalai (DIN: 03015619) as

Independent Director ends on December 17, 2022. Both the

Directors cannot be re-appointed for a further term since they

have served the maximum number of terms permitted under the

Companies Act. Hence, the Board, on the recommendation of the

Nomination and Remuneration Committee, has proposed, for the

approval of shareholders at the forthcoming AGM, the induction

of Dr R Nagendran (DIN: 08943531) and Mr S Deenadhayalan

(DIN: 01951620) as Independent Directors on the Board of the

Company. In the opinion of the Board and the Nomination and

Remuneration Committee, both the Directors are eligible and

qualified to be appointed in the Board as Independent Directors.:

Managing Director, retires by rotation and

being eligible offers himself for re-appointment.

d. Kmp

Pursuant to Sections 2(51) and 203 of the Act, 2013, Dr. Sridhar

Ganesan,: Managing

letter.

1.

Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these

secretarial records based on our audit.

2.

We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of

the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the

processes and practices, we followed provide a reasonable basis for our opinion.

3.

We have not verified the correctness and appropriateness of financial records and Books of Accounts of the company.

4.

Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of

events etc.

5.

The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our

examination was limited to the verification of procedures on test basis.

6.

The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the

management has conducted the affairs of the company.

For M/s. M. Alagar & Associates

Practising Company Secretaries

Peer Review Certificate No: 1707/2022

m. alagar

Managing Partner

Place: Chennai

FCS No: 7488/ CoP No: 8196

Date: August 02, 2022

UDIN: F007488D000729946:

letter.

1.

Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these

secretarial records based on our audit.

2.

We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of

the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the

processes and practices, we followed provide a reasonable basis for our opinion.

3.

We have not verified the correctness and appropriateness of financial records and Books of Accounts of the company.

4.

Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of

events etc.

5.

The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our

examination was limited to the verification of procedures on test basis.

6.

The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the

management has conducted the affairs of the company.

For M/s. M. Alagar & Associates

Practising Company Secretaries

Peer Review Certificate No: 1707/2022

m. alagar

Managing Partner

Place: Chennai

FCS No: 7488/ CoP No: 8196

Date: August 02, 2022

UDIN: F007488D000730056:

Managing Director

16.96 Times

-

3

Mr D P Mishra

Director

0.37 Times

4

Mr V Thirumalai

Independent Director

0.67 Times

5

Dr K C John

Independent Director

0.73 Times

6

Dr R Ravichandran

Independent Director

0.18 Times

7

Mr R Viswanathan

Independent Director

0.24 Times

8

Mr D Sathyanarayanan

Independent Director

0.49 Times

9

Dr C K Gariyali

Independent Director

0.24 Times

10

Mr D Muralidharan

Chief Financial Officer

24.44 Times

102%

11

Mr Dinesh R G,$

Company Secretary

3.34 Times

-

$ Mr. Dinesh R G was appointed w.e.f. 6th May 2021

ii.

The percentage increase in the median remuneration of employees in the Financial Year: –3.34%

iii. Number of Permanent employees in the rolls of the Company as on March 31, 2022: 743 (Standalone)

iv. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last Financial Year and its

comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional

circumstances for increase in the managerial remuneration: 10.71%

v.

Affirmation that the remuneration is as per the remuneration policy of the Company: The Company affirms remuneration is as per the

remuneration policy of the Company.

FOR AND ON BEHALF OF THE BOARD

Place: Chennai

C C paartHIpan

Date: September 05,2022

Chairman:

Managing Director, retires by rotation and being eligible offers

himself for re-appointment.

Mr. V Thirumalai, Mr. R Viswanathan, Dr. K C John,

Mr. D. Sathyanarayanan and Dr. C K Gariyali are the Independent

Directors of the Company.

The term of appointment of Dr K C John (DIN: 01067374)

as Independent Director ended on August 24, 2022. The

term of appointment of Mr V Thirumalai (DIN: 03015619) as

Independent Director ends on December 17, 2022. Both the

Directors cannot be re-appointed for a further term since they

had served the maximum number of terms permitted under the

Companies Act. Hence, the Board, on the recommendation of the

Nomination and Remuneration Committee, had proposed, for the

approval of shareholders at the forthcoming AGM, the induction

of Dr Nagendran (DIN: 08943531) and Mr Deenadhayalan

(DIN: 01951620) as Independent Directors on the Board of the

Company. In the opinion of the Board and the Nomination and

Remuneration Committee, both the Directors are eligible and

qualified to be appointed in the Board as Independent Directors.

The respective Directors have submitted all the relevant

declarations which were taken on record by the Nomination and

Remuneration Committee and the Board. Further details and the

profile of the Directors are given as part of the Notice of the AGM.

The Composition of the Board is in conformity with the requirement

of Regulation 17 of SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015 (Listing Regulations) and the

Companies Act, 2013 (Act, 2013). In the opinion of the Board,

all the Independent Directors have confirmed that they meet

the “Independence Criteria” as mentioned under Section 149

of the Act, 2013 and Regulation 16 (1)(b) of Listing Regulations.

Every Independent Director, at the first meeting of the Board in

which he/she participates as a Director and thereafter at the first

meeting of the Board in every Financial Year, gives a declaration

under Section 149(7) of the Act, 2013 that he/she meets the

criteria of independence as required under Section 149(6) of the

Act, 2013.

As required under Regulation 16 of the Listing Regulations, it is also

ensured that Independent Directors do not hold Non- Independent

Directorship position in another company, where any Non-

Independent Director of the Company is an Independent Director.

b) Board Meetings

Board and Committee meetings through video conferencing or

other audio visual means, were made available to the Directors.

As per the Companies (Meetings of Board and its Powers)

Rules, 2014 as amended from time to time, meetings through

Video Conferencing were permitted for approving the restricted

items of businesses including financial statements. During the

year, information as mentioned in Part A of Schedule II of the

CORPORATE GOVERNANCE REPORT:

Managing Director

4

Yes

2

-

1

-

Mr. D P Mishra

DIN : 02032818*

Non-Executive-Non-Independent

Director

4

Yes

-

-

1

-

Mr. V Thirumalai

DIN :03015619

Independent Director

4

Yes

-

1

2

-

Mr. R Viswanathan

DIN : 07173713

Independent Director

4

Yes

-

-

-

-

Dr. K C John

DIN : 01067374

Independent Director

4

Yes

1

2

2

-

Mr. D Sathyanarayanan

DIN : 07650566

Independent Director

4

Yes

-

-

2

-

Dr. C K Gariyali

DIN:08711546

Independent Director

4

Yes

1

-

1

-

*Mr. D P Mishra tendered his resignation with effect from the close of business hours of July 11, 2022.

Notes:

i. As required under the Regulation 17A of the Listing Regulations, none of the directors holds directorship in more than 7 (seven) listed companies

and as per declarations received, none of the Directors serves as an Independent Director in more than 7 (seven) listed companies, across the

directorships held including that in Caplin Point Laboratories Limited.:

Managing Director

Mr. V Thirumalai**

Member, Independent Director

Mr. D Sathyanarayanan

Member, Independent Director

Dr. R Ravichandran***

Member, Independent Director

*appointed as Chairman w.e.f. May 12, 2021

**appointed as Member w.e.f. May 12, 2021

***Ceases to be a Member and Chairman w.e.f. May 11, 2021

c) Meetings

The Audit Committee met four times during the year on

06.05.2021, 05.08.2021, 02.11.2021 and 03.02.2022.

The maximum time gap between two meetings did not exceed

120 days.

Name of the Members

No. of meetings attended

Dr. K C John

4

Mr. V Thirumalai

3

Dr. Sridhar Ganesan

4

Mr. D Sathyanarayanan

4

Dr. R Ravichandran

1

Dr. K C John, the Chairman of the Audit Committee was

present at the AGM held on September 28, 2021. The

Company Secretary of the company acts as a Secretary to

the Committee.

The Committee invites the Statutory Auditors and the Internal

Auditors for discussions at the meeting. Chief Financial Officer

is a permanent invitee at the Committee meetings. Members

of Senior Management team also attend the meetings

depending on the agenda.

B. Nomination and Remuneration Committee

a) Terms of Reference

In accordance with the provisions of Section 178 of the

Act, 2013 and Regulation 19 of the Listing Regulations, the

Company has formed its Nomination and Remuneration

Committee. The composition and terms of reference are in

conformity with the said provisions.

The brief description of the terms of reference of the

Committee are given below:

►

Formulate Remuneration Policy and a Policy on Board

Diversity;

►

Formulate criteria for evaluation of Directors and the

Board;

►

To ensure that the Remuneration Policy shall also

include the criteria for determining qualifications,

positive attributes and independence of a Director

and recommend to the Board a policy, relating to the

remuneration for the Directors, Key Managerial Personnel

and other employees and recommend the remuneration

to the Board;

►

Identify persons who are qualified to become Directors

and who may be appointed in Senior Management in

accordance with the criteria laid down, recommend to the

Board their appointment and removal and shall carry out

evaluation of every Director’s performance.

►

devising a policy on diversity of board of directors;

►

Recommend to the board, all remuneration, in whatever

form, payable to senior management.

The Committee acts as the Compensation Committee for

administration of Caplin Point Laboratories Limited ESOP

2015, Caplin Point Laboratories Limited ESOP 2017 and

Caplin Point Laboratories Limited ESOP 2021.:

Managing Director

Mr. D Muralidharan**

Member, Chief Financial Officer

Dr. R Ravichandran***

Member, Independent Director

* appointed as Chairman w.e.f. May 12, 2021

** appointed as Member w.e.f. May 12, 2021

*** Ceased to be Chairman and Member w.e.f. May 11, 2021

c) Meetings

The Risk Management Committee met twice during the

year on May 6, 2021 and August 5, 2021.

Name of the Members

No. of meetings attended

Mr. D Sathyanarayanan

2

Mr. Muralidharan D

1

Dr. Sridhar Ganesan

2

Mr. R Ravichandran

1

The Company Secretary of the company acts as a Secretary

to the Committee.

The Chairman of the Committee apprises the Board, the

most significant risks along with the status of action

taken by the Management for mitigating such risks and

the effectiveness of the Enterprise Risk Management

system. Details of Risk Management measures taken

by the Company have been provided in the Management

Discussion and Analysis Report which is attached to the

Board’s Report.

e. Corporate Social Responsibility Committee

The Company has constituted a Corporate Social Responsibility

(“CSR”) Committee pursuant to the provisions of Section 135

of the Act, 2013, read with Companies (Corporate Social

Responsibility) Rules, 2014.

The CSR Committee formulates and recommends to the

Board, a CSR Policy indicating the activities to be undertaken

by the Company as specified in Schedule VII of the Act, 2013.

The Committee recommends the amount of expenditure to

be incurred on the activities mentioned in the CSR Policy and

monitors the implementation of the CSR Policy.

The composition of the CSR Committee and the details of

meetings attended by its members are given below.

a) Composition

The composition of the Corporate Social Responsibility

Committee is given below:

Name of the Members Category

Mr. C C Paarthipan

Chairman

Dr. Sridhar Ganesan

Member,: Managing

Managing Director and the CFO of the Company have certified

to the Board of Directors, inter-alia, and the accuracy of financial

statements and adequacy of internal controls for the financial

reporting as required under Regulation 17(8) of the Listing

Regulations for the Financial Year ended March 31, 2022.

m) Code of Conduct

The Company has received confirmations from the Board

(incorporating duties of Independent Directors) and the Senior

Management personnel regarding their adherence to the Code of

Conduct. The Annual Report of the Company contains a certificate

by the: Managing Director, on the compliance declarations

received from Board of Directors and Senior Management. The

Code has been hosted on the Company’s website at https://www.

caplinpoint.net/index.php/corporate-governance/

16. NON-MANDATORY REQUIREMENTS

i. The Company maintains an office for the Non-Executive

Managing Director:

Managing Director

04

Telephone number

044 28156653

05

e-mail id

info@caplinpoint.net

2.

Principle-wise (as per NVGs) BR Policy/policies

(a) Details of compliance (Reply in Y/N)

No. Questions

P 1

Business

Ethics

P 2

Product

responsibility

P 3

Well being of

Employees

P 4

Stakeholder

engagement

P 5

Human

Rights

P 6

Environment

P 7

Public

policy

P 8

CSR

P 9

Customer

relation

01 Do you have a policy/ policies for....

YES

YES

YES

YES

YES

YES

YES

YES

YES

02 Has

the

policy

being

formulated

in

consultation with the relevant stakeholders?

YES

YES

YES

YES

YES

YES

YES

YES

YES

03 Does the policy conform to any national /

international standards? If yes, specify? (50

words)

The policies conform to the guidelines / standards of Companies Act, 2013 and other Statutory

Acts, Regulations, Notifications, etc. The policies / standards are at par with generally accepted

practices for the respective principles.

04 Has the policy being approved by the Board?

Is yes, has it been signed by MD/ owner/

CEO/ appropriate Board Director?

YES

YES

YES

YES

YES

YES

YES

YES

YES

05 Does the company have a specified committee

of the Board/ Director/ Official to oversee the

implementation of the policy?

YES

YES

YES

YES

YES

YES

YES

YES

YES

06 Indicate the link for the policy to be viewed

online?

https://www.caplinpoint.net/index.php/corporate-governance/

07 Has the policy been formally communicated to

all relevant internal and external stakeholders?

YES

YES

YES

YES

YES

YES

YES

YES

YES

08 Does the Company have in-house structure to

implement the policy/ policies

YES

YES

YES

YES

YES

YES

YES

YES

YES

09 Does the Company have a grievance redressal

mechanism related to the policy/ policies to

address stakeholders’ grievances related to

the policy/ policies?

YES

YES

YES

YES

YES

YES

YES

YES

YES

10 Has the company carried out independent

audit/ evaluation of the working of this policy

by an internal or external agency?

YES

YES

YES

YES

YES

YES

YES

YES

YES:

Letter

of Credit, on the basis of security of Land and factory building.

According to information and explanation given to us, the quarterly

statement filed by the Company with the bank are in agreement

with the books of account of the Company.

iii) According to the information and explanations given to us, during

the year, the Company has not made any guarantee or security or

granted any advances in the nature of loan, secured or unsecured to

companies, firms, limited liability partnerships or any other parties

except an unsecured Loan to one of its Subsidiary company and

investment made in Caplin Onco Ltd(Wholly Owned Subsidiary)

during the year. Details of the Loan is stated in sub-clause (A) below

(a) A. According to the information and explanation given to us and

based on the audit procedures carried on by us, the company

has granted loan to one of its subsidiary on an arms length

basis, the details of which are as below.

Particulars

amount

(` in crores)

Aggregate amount during the year

39.75

Balance outstanding as at balance sheet date

39.75

B. According to the information and explanation given to us and

based on the audit procedures carried on by us, the company

has not granted any loan to any other parties. Hence, the

details required are not discussed.

(b) According to the information and explanation given to us and

based on the audit procedures carried on by us, we are of the

opinion that the terms and conditions of loans provided are not

prejudicial to the interest of the Company.

(c) According to the information and explanation given to us, the

repayment of Principal and Interest has been stipulated and

receipts are regular.:

Managing Director

ICAI Membership No. 201023

DIN:01218784

DIN:06819026

Place : Chennai

muralidharan d

dinesh R G

Date : 12th May, 2022

Chief Financial Officer

Company Secretary:

Managing Director

ICAI Membership No. 201023

DIN:01218784

DIN:06819026

Place : Chennai

muralidharan d

dinesh R G

Date : 12th May, 2022

Chief Financial Officer

Company Secretary:

Managing Director

ICAI Membership No. 201023

DIN:01218784

DIN:06819026

Place : Chennai

muralidharan d

dinesh R G

Date : 12th May, 2022

Chief Financial Officer

Company Secretary:

Managing Director

ICAI Membership No. 201023

DIN:01218784

DIN:06819026

Place : Chennai

muralidharan d

dinesh R G

Date : 12th May, 2022

Chief Financial Officer

Company Secretary:

Letter of Credit and Bank Guarantee .

note 38: emPloYee BeneFitS

(i) Defined Contribution Plan:

Contributions to defined contributions schemes as employees’ state insurance, labour welfare fund, etc are charged as expense based on the

amount of contribution required to be made as and when services are rendered by the employees. Company’s provident fund contributions is made

to a Government administered fund and charged as expense to the Statement of Profit and Loss. The contributions payable to these plans are at

the rates specified in the rules of the schemes.

The Company recognized ` 1.70 Crores (Previous year ` 1.48 Crores ) towards provident and pension fund contributions in the Statement of Profit

and Loss.:

manaGinG diRectoR/WHole-time diRectoRS

Particulars

For the Financial

Year ended

march 31, 2022

For the Financial

Year ended

march 31, 2021

Salaries

0.52

0.54

Contribution to provident and other funds

0.04

0.02

total *

0.56

0.56

* Refer note 45 (C)

note 41: ReSeaRcH and deVeloPment eXPendituRe

Particulars

For the Financial

Year ended

march 31, 2022

For the Financial

Year ended

march 31, 2021

Capital expenditure included in Fixed Assets

0.57

6.61

Revenue expenditures incurred during the Financial Year

23.87

19.40

total

24.44

26.01

note 42: auditoRS’ RemuneRation comPRiSeS oF FeeS: (eXcludinG aPPlicaBle taX)

Particulars

For the Financial

Year ended

march 31, 2022

For the Financial

Year ended

march 31, 2021

For Statutory Audit

0.13

0.13

For Tax Audit

0.03

0.03

For Others

0.01

0.01

total

0.17

0.17:

Managing Director from 28.03.2015

Mr. D Muralidharan

– Chief Financial Officer from 19.02.2016

Mr. Dinesh R G

– Company Secretary from 06.05.2021

Mr. Vinod Kumar Srinivasan

– Company Secretary from 11-01-2019 to 05-02-2021

(c) details of transactions that have taken place during the Financial Year with Key management Personnel/Related Party:

Particulars

For the Financial

Year ended

march 31, 2022

For the Financial

Year ended

march 31, 2021

Remuneration*

Mr.Vivek Siddharth-Chief Operating officer (Related Party)

0.19

0.12

Dr. Sridhar Ganesan

0.56

0.56

Mr. D Muralidharan**

0.80

0.40

Mr. R G Dinesh

0.11

-

Mr. Vinod Kumar Srinivasan

-

0.09

* Remuneration includes Basic salary, House Rent Allowance, Special Allowance,Leave Travel Assistance, Medical Reimbursement, contribution

to Provident Fund and such other perquisites, payable to Key Management Personnel, as per Company Policy except Provision for contribution to

gratuity fund, leave encashment on retirement and other defined benefits which are made based on acturial valuation on an overall Company basis.:

Managing Director

ICAI Membership No. 201023

DIN:01218784

DIN:06819026

Place : Chennai

muralidharan d

dinesh R G

Date : 12th May, 2022

Chief Financial Officer

Company Secretary:

Managing Director

ICAI Membership No. 201023

DIN:01218784

DIN:06819026

Place : Chennai

muralidharan d

dinesh R G

Date : 12th May, 2022

Chief Financial Officer

Company Secretary:

Managing Director

ICAI Membership No. 201023

DIN:01218784

DIN:06819026

Place : Chennai

muralidharan d

dinesh R G

Date : 12th May, 2022

Chief Financial Officer

Company Secretary:

Managing Director

ICAI Membership No. 201023

DIN:01218784

DIN:06819026

Place : Chennai

muralidharan d

dinesh R G

Date : 12th May, 2022

Chief Financial Officer

Company Secretary

(All amounts are in ` Crores unless otherwise stated):

Managing Director

ICAI Membership No. 201023

DIN:01218784

DIN:06819026

Place : Chennai

muralidharan d

dinesh R G

Date : 12th May, 2022

Chief Financial Officer

Company Secretary

(All amounts are in ` Crores unless otherwise stated):

Letter of Credit and Bank Guarantee.

NOTE 39: EMPLOYEE BENEFITS

(i) Defined Contribution Plan:

Contributions to defined contributions schemes as employees’ state insurance, labour welfare fund, etc are charged as expense based on the

amount of contribution required to be made as and when services are rendered by the employees. Company’s provident fund contributions is made

to a Government administered fund and charged as expense to the Statement of Profit and Loss. The contributions payable to these plans are at

the rates specified in the rules of the schemes.

The Company recognized ` 3.67 Crores (previous year ` 3.34 Crores) towards provident and pension fund contributions in the Statement of Profit

and Loss.:

MANAGING DIRECTOR/WHOLE-TIME DIRECTORS OF THE PARENT COMPANY

Particulars

For the Financial

Year ended

March 31, 2022

For the Financial

Year ended

March 31, 2021

Salaries

0.52

0.54

Contribution to provident and other funds

0.04

0.02

total *

0.56

0.56

* Refer note 46 (c )

NOTE 42: RESEARCH AND DEVELOPMENT EXPENDITURE

Particulars

For the Financial

Year ended

March 31, 2022

For the Financial

Year ended

March 31, 2021

Capital expenditure included in Fixed Assets

3.20

9.72

Revenue expenditures incurred during the Financial Year

59.27

53.69

total

62.47

63.41

NOTE 43: AUDITORS’ REMUNERATION COMPRISES OF FEES: (EXCLUDING APPLICABLE TAX)

Particulars

For the Financial

Year ended

March 31, 2022

For the Financial

Year ended

March 31, 2021

For Statutory Audit

0.47

0.41

For Tax Audit

0.20

0.22

For Others

0.01

0.07

total

0.68

0.70:

Director's relatives are interested

Not Applicable

Not Applicable

Hainan Jointown Caplin point Pharmaceutical

Company Limited, (China)

Associate

39.00%

39.00%

Sunsole Solar Pvt Ltd ##

Associate of CSL

28.01%

-

** The Company’s Associate entity in China namely Hainan Jointown Caplinpoint Pharmaceutical Company Limited has been liquidated and the

amount invested by the Company in this joint venture has been received in full in April 2022

## Equity shares subscribed during the year FY 2021-22 for 28.01% stake in the entity, to meet the minimum statutory norms for purchase of

Captive Solar power.

(b) Key Managerial Personnel

Dr. Sridhar Ganesan

–: Managing

Managing Director

ICAI Membership No. 201023

DIN:01218784

DIN:06819026

Place : Chennai

muralidharan d

dinesh R G

Date : 12th May, 2022

Chief Financial Officer

Company Secretary:

Managing Director of the company

To consider and if thought fit, to pass the following resolution as an

ordinary Resolution:

“ReSoLVeD tHAt pursuant to provisions of Sections 196, 197 and

203 read with Schedule V and other applicable provisions, if any,

of the Companies Act, 2013, and the Companies (Appointment and

ReSoLVeD FURtHeR tHAt the Board of Directors of the Company

(hereinafter referred to as ‘Board’ which term shall be deemed to

include the Audit Committee of the Board) be and is hereby authorised

to do all such acts, deeds, matters and things as it may deem fit in

its discretion and to take all such steps as may be required in this

connection including finalizing and executing necessary contract(s),

arrangement(s) and such other documents as may be required,

seeking all necessary approvals to give effect to this resolution, for

and on behalf of the Company, to delegate all or any of its powers

conferred under this resolution to any Director or Key Managerial

Personnel or any officer / executive of the Company”.

7.

Approval for providing loans and guarantees under Section 185 of

the companies Act, 2013

To consider and if thought fit, to pass the following resolution as a

Special Resolution:

“ReSoLVeD tHAt, pursuant to Section 185 and all other applicable

provisions of the Companies Act, 2013 and Rules made thereunder as

amended from time to time, consent of the members of the Company

be and is hereby accorded to the Board of Directors (hereinafter

referred to as the Board, which term shall be deemed to include,

unless the context otherwise required, any committee of the Board:

Managing Director of the Company for the period

of two years with effect from August 25, 2022, at a remuneration

recommended by the Nomination & Remuneration Committee as set

out below:-

1. Salary: ` 55,20,000 per annum

2. Allowances and Perquisites:

As may be determined by the Nomination and Remuneration

Committee including employee stock options

3. Retirement benefits:

Contribution to Provident fund, superannuation fund and gratuity

as per the rules of the fund/scheme in force from time to time.

4. General:

i) Perquisites shall be valued in terms of actual expenditure

incurred by the Company in providing benefit to the employees.

However, in cases where the actual amount of expenditure

cannot be ascertained with reasonable accuracy (including

car provided for official and personal purposes) the perquisites

shall be valued as per income tax rules;

ii) The following shall not be considered as part of perquisites:

a. Contribution to provident fund, superannuation fund or

annuity fund to the extent that is singly or put together are

not taxable under the Income Tax Act, 1961;

b. Gratuity payable at a rate not exceeding half a month’s

salary for each completed year of service; and

c. Encashment of leave at the end of the tenure.

iii) The aggregate remuneration (including salary, allowances,

perquisites, incentive and retirement benefits) for any

financial year shall be subject to an overall ceiling of 10% of

the net profits of the Financial year computed in the manner

prescribed under the Act;

iv) Dr Sridhar Ganesan will not be entitled to any sitting fees for

attending meetings of the Board and the committees thereof;

v) Dr Sridhar Ganesan will be subject to all other service conditions

as applicable to any other employees of the Company;

vi) Dr Sridhar Ganesan will be liable to retire by rotation, in

terms of relevant provisions of Section 152 of the Companies

Act,2013;

ReSoLVeD FURtHeR tHAt the Board of Directors of the Company be

and is hereby authorised to alter and vary the scope of remuneration

of Dr Sridhar Ganesan, to the extent recommended by the nomination

and remuneration committee from time to time as may be considered

appropriate, subject to the overall limits specified by this resolution

and the Companies Act,2013.

ReSoLVeD FURtHeR tHAt the Board of Directors be and is hereby

authorized to do all acts and take all such steps as may be necessary,

proper or expedient to give effect to this resolution.”

9. to consider and approve the Appointment of Dr R. Nagendran as

an independent Director of the company

To consider and if thought fit, to pass the following resolution as an

Special Resolution:

“ReSoLVeD tHAt pursuant to the provisions of Sections 149, 150,

152 read with Schedule IV and other applicable provisions of the

Companies Act, 2013, the Companies (Appointment and Qualifications

of Directors) Rules, 2014, Regulation 16(1)(b), Regulation 17,

Regulation 25 and other applicable regulations of the Securities

and Exchange Board of India (Listing Obligations and Disclosure

Requirements) Regulations, 2015 as amended from time to time,

Dr R. Nagendran (DIN: 08943531), who was recommended by the

Nomination and Remuneration Committee and the Board, be and is

hereby appointed as an Independent Director of the Company for a

term of five years i.e., from the conclusion of the 31st Annual General

Meeting and whose term is not liable to retirement by rotation.

“ReSoLVeD FURtHeR tHAt the Board of Directors be and is hereby

authorized to do all acts and take all such steps as may be necessary,

proper or expedient to give effect to this resolution.”:

letter to the Scrutinizer by email to alagar@

geniconsolutions.com with a copy marked to evoting@nsdl.co.in.

4.

The attendance of the members attending the AGM through VC/

OAVM will be counted for the purpose of ascertaining the quorum

under Section 103 of the Act, 2013.

5.

Brief resume, details of Directors shareholding and Directors inter-

se relationship of Directors seeking appointment /Re-appointment

as required under Regulation 36 (3) of SEBI (Listing Obligations

& Disclosure Requirements) Regulations, 2015, are provided as

Annexure to this Notice.

6.

Members may note that the Board has recommended a Final

Dividend of ` 2/- per equity share. The Register of Members and

Share Transfer Books of the Company will be closed from September

23, 2022 to September 29, 2022 (both days inclusive) for the

purpose of AGM and final dividend.

7.

The final dividend as recommended by the Board of Directors, if

approved at the AGM, will be paid as per the Statutory timelines to

those members, whose names appear in the Register of Members on

September 22, 2022 and in respect of shares held in dematerialized

form, dividend will be paid to members whose names are furnished

by National Securities Depository Limited and Central Depository

Services (India) Limited as beneficial owners as on that date.

8.

Members holding shares in physical forms are requested to notify

and change in their address to the Company / Share Transfer Agents

quoting Register Folio number. Members holding shares in electronic

form are requested to intimate any change in their address or bank

mandates to their respective Depository Participants. Members

are encouraged to utilize the Electronic Clearing System (ECS) for

receiving dividend. For members who have not updated their bank

account details, dividend warrants / demand drafts / cheques will

be sent to their registered addresses in the mode permitted for the

purpose.

9.

Members may note that the Income-tax Act, 1961, (“the IT Act”) as

amended by the Finance Act, 2020, mandates that dividend paid or

distributed by a company on or after April 1, 2020 shall be taxable

in the hands of members. The Company shall therefore be required

to deduct tax at source (“TDS”) at the time of making the payment of

final dividend. To enable us to determine the appropriate TDS rate as

applicable, members are requested to submit relevant documents

and/or update their Residential Status, PAN, Category as per the

IT Act with their Depository Participants or in case shares are held

in physical form, with the Company by sending email corpserv@

integratedindia.in.

However, no tax shall be deducted on the dividend payable to resident

individual shareholders if the total dividend to be received by them

during financial year 2022-23 does not exceed ` 5,000, and also in

cases where members provide Form 15G / Form 15H (Form 15H is

applicable to resident individual shareholders aged 60 years or more):

letter etc. with attested specimen

signature of the duly authorized signatory (ies) who are authorized to

vote, to the Scrutinizer by e-mail alagar@geniconsolutions.com with

a copy marked to evoting@nsdl.co.in. Institutional shareholders (i.e.

other than individuals, HUF, NRI etc.) can also upload their Board

Resolution / Power of Attorney / Authority: Letter etc. by clicking

on “Upload Board Resolution / Authority Letter” displayed under

“e-Voting” tab in their login.

2.

It is strongly recommended not to share your password with any other

person and take utmost care to keep your password confidential.

Login to the e-voting website will be disabled upon five unsuccessful

attempts to key in the correct password. In such an event, you will need

to go through the “Forgot User Details/Password?” Or “Physical User

Reset Password?” option available on www.evoting.nsdl.com to reset

the password.

3.

In case of any queries, you may refer the Frequently Asked Questions

(FAQs) for Shareholders and e-voting user manual for Shareholders

available at the download section of www.evoting.nsdl.com or call on

toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request

to Ms. Pallavi Mhatre, Senior Manager at evoting@nsdl.co.in

Process for those shareholders whose email ids are not registered with

the depositories for procuring user id and password and registration of

e mail ids for e-voting for the resolutions set out in this notice:

1.

In case shares are held in physical mode please provide Folio No., Name

of shareholder, scanned copy of the share certificate (front and back),

PAN (self-attested scanned copy of PAN card), AADHAR (self-attested

scanned copy of Aadhar Card) by email to corpserv@integratedindia.in.

2.

In case shares are held in demat mode, please provide DPID-CLID (16

digit DPID + CLID or 16 digit beneficiary ID), Name, client master or

copy of Consolidated Account statement, PAN (self-attested scanned

copy of PAN card), AADHAR (self-attested scanned copy of Aadhar

Card) to corpserv@integratedindia.in.

3.

If you are an Individual shareholder holding securities in demat

mode, you are requested to refer to the login method explained at

step 1 (A) i.e. Login method for e-Voting and joining virtual meeting

for Individual shareholders holding securities in demat mode.

4.

Alternatively members may send a request to evoting@nsdl.co.in

for procuring user id and password for e-voting by providing above

mentioned documents.

5. In terms of SEBI circular dated December 9, 2020 on e-Voting

facility provided by Listed Companies, Individual shareholders

Managing Director and Dr C K

Gariyali, Independent Director also serve on the Board of CSL.

8.

Valuation or other external report relied upon by the

listed entity in relation to the transactions

Not applicable.

in the Company and CSL. The Board recommends this ordinary resolution

for approval of the shareholders. None of the Related Parties of the

company shall vote to approve the resolution.

iteM No. 7

Approval for providing loans and guarantees under Section 185 of the

companies Act, 2013

The Company will be required to render support for the business

requirements of its Subsidiary companies from time to time. In the light

of the provisions of Companies Act, 2013, the Company, with the approval

of shareholders by way of special resolution, would be in a position to

provide financial assistance by way of loan or give guarantee or provide

security in respect of loans taken by its Subsidiaries for their principal

business activities. This would exclude wholly-owned Subsidiaries of

Any subsequent material modifications to the transactions, as per the

Related Party Transaction Policy of the Company, shall be subject to prior

approval of the shareholders. The Audit Committee of the Company had

reviewed the transaction and had recommended the same for approval

of the shareholders at their meeting held on September 5, 2022. The

management of the Company had provided the Audit Committee with

relevant details of the Related Party Transactions, including its material

terms and conditions, tenure and basis of pricing as summarised in the

table above. In view of the same, the material related party transactions

as set out in the resolution is placed before the shareholders for their

approval by way of an ordinary resolution.

None of the Directors and Key Managerial Personnel of the Company

or their respective relatives are concerned or interested, financially or

otherwise, in the above resolution except to the extent of their Directorship:

Managing Director and Dr C K Gariyali, Independent Director serve on the

Board of CSL and hence to that extent are interested in the resolution.

Except as above, none of the Directors / Key Managerial Personnel of

the Company / their relatives is, in any way, concerned or interested,

financially or otherwise, in the resolution.

iteM No. 8

Re-appointment of Dr Sridhar Ganesan as the: Managing

